Differential diagnostics of inflammatory changes and epithelial neoplasia of extrahepatic bile ducts
- 16 April 2026
- journal article
- abstracts
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 88 (2) , 72-79
Abstract
Objective. To investigate the histological and immunohistochemical characteristics of epithelial neoplasia of the extrahepatic bile ducts (EHBD) and to develop a diagnostic algorithm. Material and methods. The study included 104 patients. All patients underwent biliary tract biopsy. Morphological and immunohistochemical parameters were compared in biopsies with inflammation, low- and high-grade biliary intraepithelial neoplasia (BilIN), low- and high-grade intraductal papillary neoplasia (IPNB), and cholangiocarcinoma (CC). The main parameters in the study of the histological characteristics of epithelial neoplasia of the EHBD were: cellular atypia, nuclear polymorphism, nuclear polarity, the state of the brush border, inflammatory infiltration, and histological architecture. Immunohistochemical studies were performed using antibodies to MUC1, MUC2, MUC5AC, MUC6, and CD10. When studying the IHC characteristics of epithelial neoplasms of the EHBD, the localization of the reaction in epithelial cells, its intensity, and prevalence were assessed, and specificity and sensitivity were evaluated. Statistical analysis of the data used the two-sided Pearson χ2 criterion (p<0.05). Results. Based on the results of the morphological stage of the study, a scale for assessing the degree of dysplasia in biopsy specimens was developed; a certain number of points were assigned to each type of epithelial neoplasia of the EHBD. Based on the results of the IHC study, taking into account statistically significant changes, an immunophenotype was established for each type of epithelial neoplasia of the EHBD: inflammation and BilIN LG — MUC1, MUC2, MUC6, CD10; BilIN HG — MUC1, MUC2, MUC5AC, MUC6; IPNB LG — MUC1, MUC2, MUC5AC, MUC6, CD10; IPNB HG — MUC1, MUC2, MUC5AC, MUC6; CC — MUC1, MUC5AC, MUC6. For differential diagnosis of the degree of dysplasia in epithelial neoplasia of the EHBD, it is recommended to use an IHC panel with the presence of antibodies to MUC1, MUC2, CD10. It is proposed to use antibodies to MUC2, MUC5AC and MUC6 as an IHC panel for differential diagnosis of IPNB subtypes. Conclusion. Clear morphological and immunohistochemical criteria for the differential diagnosis of non-invasive lesions of the EHBD, inflammation and cholangiocarcinoma have been identified, and an algorithm for the comprehensive differential diagnosis of epithelial neoplasia of the EHBD has been developed.Keywords
This publication has 17 references indexed in Scilit:
- Intraductal papillary neoplasms of the bile duct: a European retrospective multicenter observational study (EUR-IPNB study)International Journal of Surgery, 2023
- Intraductal papillary neoplasm of the bile duct – A comprehensive reviewAdvances in Medical Sciences, 2021
- Interobserver agreement in pathologic evaluation of bile duct biopsiesHuman Pathology, 2021
- Molecular classification and therapeutic targets in extrahepatic cholangiocarcinomaJournal of Hepatology, 2020
- The Pathologic and Genetic Characteristics of the Intestinal Subtype of Intraductal Papillary Neoplasms of the Bile DuctAmerican Journal of Surgical Pathology, 2019
- Pathological diagnosis of flat epithelial lesions of the biliary tract with emphasis on biliary intraepithelial neoplasiaJournal of Gastroenterology, 2013
- Precancerous lesions of the biliary treeBest Practice & Research Clinical Gastroenterology, 2013
- Diagnostic Utility of CD10 in Benign and Malignant Extrahepatic Bile Duct LesionsAmerican Journal of Surgical Pathology, 2012
- Sox17 Regulates Organ Lineage Segregation of Ventral Foregut Progenitor CellsDevelopmental Cell, 2009
- Proposal of histological criteria for intraepithelial atypical/proliferative biliary epithelial lesions of the bile duct in hepatolithiasis with respect to cholangiocarcinoma: Preliminary report based on interobserver agreementPathology International, 2005